Surprising news came this week that the maker of Pradaxa, Boehringer Ingelheim, is having a banner year for sales, and a large part of that id due to the controversial anticoagulant drug Pradaxa itself.
The news came as a shock to many given the fact that the FDA launched an investigation into the safety of Pradaxa in December, 2011, after receiving hundreds of reports of injury or death from patients experiencing uncontrollable internal bleeding.
However, prior to the warning, Pradaxa was one of the most popular drugs in the world for those suffering from atrial fibrillation.
The German drugmaker announced in April that it expected a nearly 10% growth in sales for 2012 due to it’s respiratory drug Spiriva and Pradaxa, which has now reached the mark of more than $1 billion in sales.
The news makes it very unlikely that the company will recall Pradaxa and will resist label warnings despite nearly 1,000 reports of injury or death and many pending lawsuits.